Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Urology
Published in: BMC Urology 1/2020

01-12-2020 | Kidney Cancer | Research article

Axitinib as a third or further line of treatment in renal cancer: a single institution experience

Authors: G. Tsironis, M. Liontos, A. Kyriazoglou, K. Koutsoukos, A. Tsiara, M. Kaparelou, R. Zakopoulou, A. Cohen, E. Skafida, S. Fontara, F. Zagouri, A. Bamias, M. A. Dimopoulos

Published in: BMC Urology | Issue 1/2020

Login to get access

Abstract

Background

Kidney cancer is a lethal neoplasm that affects several thousands of people every year. Renal cell carcinoma (RCC) is the most common histologic type. Recent developments in the therapeutic approach include antiangiogenic targeted approaches and Immunotherapy. Thus, the therapeutic algorithm of RCC patients and the survival outcomes have changed dramatically.

Methods

Herein we present a retrospective study of the patients treated in our Department with an antiangiogenic agent -Axitinib, a tyrosine kinase inhibitor- as a third or further line treatment. Statistical analysis was performed with SPSS, including the available clinicopathological data of the patients included.

Results

Axitinib was found to be active in patients who received this treatment beyond second line. The toxicity profile of this regimen did not reveal any unknown adverse events.

Conclusions

Our real world data reflect that axitinib is a safe and effective option, even beyond the second line.
Literature
1.
Zagouri F, Peroukidis S, Tzannis K, Kouloulias V, Bamias A, Hellenic Genito-Urinary Cancer G. Current clinical practice guidelines on chemotherapy and radiotherapy for the treatment of non-metastatic muscle-invasive urothelial cancer: a systematic review and critical evaluation by the Hellenic Genito-urinary Cancer group (HGUCG). Crit Rev Oncol Hematol. 2015;93(1):36–49.CrossRef
2.
Bamias A, Escudier B, Sternberg CN, Zagouri F, Dellis A, Djavan B, Tzannis K, Kontovinis L, Stravodimos K, Papatsoris A, et al. Current clinical practice guidelines for the treatment of renal cell carcinoma: a systematic review and critical evaluation. Oncologist. 2017;22(6):667–79.CrossRef
3.
Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;353(23):2477–90.CrossRef
4.
Shingarev R, Jaimes EA. Renal cell carcinoma: new insights and challenges for a clinician scientist. Am J Physiol Renal Physiol. 2017;313(2):F145–54.CrossRef
5.
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24.CrossRef
6.
Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061–8.CrossRef
7.
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–34.CrossRef
8.
Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103–11.CrossRef
9.
Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, et al. Cabozantinib versus Everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1814–23.CrossRef
10.
Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449–56.CrossRef
11.
Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–81.CrossRef
12.
Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, Jassem J, Zolnierek J, Maroto JP, Mellado B, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473–82.CrossRef
13.
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, et al. Nivolumab versus Everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13.CrossRef
14.
Fogli S, Porta C, Del Re M, Crucitta S, Gianfilippo G, Danesi R, Rini BI, Schmidinger M. Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs. Cancer Treat Rev. 2020;84:101966.CrossRef
15.
Gulati S, Vaishampayan U. Current state of systemic therapies for advanced renal cell carcinoma. Curr Oncol Rep. 2020;22(3):26.CrossRef
16.
Angulo JC, Shapiro O. The Changing Therapeutic Landscape of Metastatic Renal Cancer. Cancers (Basel). 2019;11(9):1227.
17.
Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67(5):913–24.CrossRef
18.
Motzer RJ, Porta C, Vogelzang NJ, Sternberg CN, Szczylik C, Zolnierek J, Kollmannsberger C, Rha SY, Bjarnason GA, Melichar B, et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(3):286–96.CrossRef
19.
Calvo E, Escudier B, Motzer RJ, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Ravaud A, et al. Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer. 2012;48(3):333–9.CrossRef
20.
Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931–9.CrossRef
21.
Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, Oudard S, Gore ME, Tarazi J, Hariharan S, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013;14(6):552–62.CrossRef
22.
Pal SK, Signorovitch JE, Li N, Zichlin ML, Liu Z, Ghate SR, Perez JR, Vogelzang NJ. Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the USA. Int J Urol. 2017;24(4):272–8.CrossRef
23.
MacLean E, Cisar L, Mehle K, Eremina D, Quigley JM. Real-World Axitinib Use in the United States: A Retrospective Study Using Linked Datasets. J Manag Care Spec Pharm. 2016;22(6):723–732u.PubMed
24.
Hutson TE, Jiao X, Wilson T, Cisar L, MacLean EA. Axitinib in metastatic renal cell carcinoma: patient characteristics and treatment patterns in US community oncology centers. Future Oncol. 2017;13(15):1323–32.CrossRef
25.
Kyriakopoulos CE, Chittoria N, Choueiri TK, Kroeger N, Lee JL, Srinivas S, Knox JJ, Bjarnason GA, Ernst SD, Wood LA, et al. Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium. Clin Genitourin Cancer. 2015;13(2):e79–85.CrossRef
26.
Rini BI, Gruenwald V, Jonasch E, Fishman MN, Tomita Y, Michaelson MD, Tarazi J, Cisar L, Hariharan S, Bair AH, et al. Long-term duration of first-line Axitinib treatment in advanced renal cell carcinoma. Target Oncol. 2017;12(3):333–40.CrossRef
27.
Molina AM, Jia X, Feldman DR, Hsieh JJ, Ginsberg MS, Velasco S, Patil S, Motzer RJ. Long-term response to sunitinib therapy for metastatic renal cell carcinoma. Clin Genitourin Cancer. 2013;11(3):297–302.CrossRef
28.
Smaletz O, Chacon M, de Oliveira KL, de Carvalho Rocha DR, Cardoso FC. Long-term benefit of sunitinib in patients with metastatic renal cell carcinoma in Latin America: retrospective analysis of patient clinical characteristics. Onco Targets Ther. 2016;9:7309–14.CrossRef
29.
Tannir NM, Figlin RA, Gore ME, Michaelson MD, Motzer RJ, Porta C, Rini BI, Hoang C, Lin X, Escudier B. Long-term response to Sunitinib treatment in metastatic renal cell carcinoma: a pooled analysis of clinical trials. Clin Genitourin Cancer. 2017;S1558-7673(17)30171–4.
30.
Park J, Jiao X, Ghate S, Wilson T, Ahmad QI, Vogelzang NJ. Predictors of long-term response with Pazopanib in patients with advanced renal-cell carcinoma. Clin Genitourin Cancer. 2018;16(4):293–7.
31.
Sbrana A, Biasco E, Paolieri F, Palesandro E, Caserta C, Iacovelli R, Detti B, Santini D, Mosca A, Morelli F, et al. Long-term response to first-line Pazopanib therapy in mRCC patients: a multicenter Italian experience. Anticancer Res. 2018;38(8):4913–8.CrossRef
32.
Zhang HL, Qin XJ, Wang HK, Gu WJ, Ma CG, Shi GH, Zhou LP, Ye DW. Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective study. Oncotarget. 2015;6(34):36870–83.CrossRef
Metadata
Title
Axitinib as a third or further line of treatment in renal cancer: a single institution experience
Authors
G. Tsironis
M. Liontos
A. Kyriazoglou
K. Koutsoukos
A. Tsiara
M. Kaparelou
R. Zakopoulou
A. Cohen
E. Skafida
S. Fontara
F. Zagouri
A. Bamias
M. A. Dimopoulos
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2020
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-020-00618-1

Other articles of this Issue 1/2020

BMC Urology 1/2020 Go to the issue

Case report

Spontaneous vesicorectal fistula: a rare complication of neurogenic bladder

Research article

Efficacy of urination in alleviating man’s urethral pain associated with flexible cystoscopy: a single-center randomized trial

Research article

Small renal masses in Latin-American population: characteristics and prognostic factors for survival, recurrence and metastasis – a multi-institutional study from LARCG database

Research article

Prostate artery embolization has long term efficacy for treatment of severe lower urinary tract symptoms from giant prostatic hyperplasia

Case report

Myxoma of the renal pelvis masquerading pelviureteric stenosis: conservative limited resection with renal preservation: case presentation and literature review

Case report

Transverse testicular ectopia with Müllerian duct remnant in an incarcerated congenital inguinal hernia – a case report